Our study underscores the promising efficacy of T-Dxd and bevacizumab in the treatment of HER2-amplified rectal cancer with brain metastases, demonstrating significant tumor shrinkage consistent with partial remission. This evidence concerns the gene ERBB2 and rectal cancer.